Results 221 to 230 of about 6,944 (246)

GLP-1RA based therapies in the young and old

Current Opinion in Endocrinology, Diabetes & Obesity
Purpose of review Obesity is recognized as a “gateway” chronic, progressive disease of dysfunctional adipocytes. Glucagon-like peptide-1 receptor agonist-based therapies (GLP1BTs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with/without glucose-dependent insulinotropic polypeptide (GIP), have demonstrated ...
Georgia, Rigas, Shirley, Alexander, Cilla J, Haywood   +2 more
openaire   +2 more sources

Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA

Current Diabetes Reports, 2018
In addition to their effects on glycemic control, two specific classes of relatively new anti-diabetic drugs, namely the sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated reduced rates of major adverse cardiovascular events (MACE) in subjects with type 2 diabetes (T2D) at high ...
Dorrin Zarrin, Khat, Mansoor, Husain
openaire   +2 more sources

Kniearthrose: Lange GLP-1RA-Therapie ist krankheitsmodifizierend

Aktuelle Rheumatologie
Eine Gewichtsreduktion gilt als eine der ersten Maßnahmen bei Kniearthrose (KOA). Jüngste Erkenntnisse deuten darauf hin, dass bei Diabetes mellitus Typ 2 empfohlene Glucagonlike-Peptid-1-Rezeptor-Agonisten (GLP-1RAs), die eine Gewichtsreduktion bewirken, eine geringe Verbesserung ...
openaire   +1 more source

1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial

Diabetes, 2019
LixiLan-G (NCT02787551) was a randomized, open-label, 26-week trial in T2D participants (pts) with HbA1c 7‒9%, receiving maximum tolerated doses of a once- or twice-daily (QD/BID) GLP-1 RA or a once-weekly (QW) GLP-1 RA with metformin ± pioglitazone ± SGLT2i. Pts were randomized to continue their GLP-1 RA regimen with supported adherence or switch to a
JULIO ROSENSTOCK, LAWRENCE BLONDE, STEFANO DEL PRATO, ROBERT R. HENRY, NAIM SHEHADEH, ELISABETH NIEMOELLER, ELISABETH SOUHAMI, JUNLONG WU, XIANGLING WANG, CHEN JI, VANITA R. ARODA   +10 more
openaire   +1 more source

Semaglutide 2.4 Mg: The Latest GLP-1RA Approved for Obesity

Journal of Investigative Medicine, 2022
Ricardo Villela, Ricardo Correa
openaire   +2 more sources

GLP-1RAs may cause intolerable gastrointestinal AEs

Reactions Weekly, 2023
openaire   +1 more source

766-P: GLP-1RA, Oral Formulation and Its Preclinical Evaluations

Diabetes
Introduction and Objective: The remarkable efficacy of GLP-1RAs, which has had a significant impact in real world, is gradually advancing towards firstly once-a-month injectable sustained release formulation and ultimately moving toward oral formulations.
JIN JUNG, JIHO LEE, GILAH KIM
openaire   +1 more source

IP06-36 CHARACTERIZING KIDNEY STONE EPISODES BY GLP-1RA MEDICATION IN GLP-1RA USERS

Journal of Urology
Shreya Thiagarajan, Sofia Di Scipio, Kidest Wolde, Areeba Sadiq   +3 more
openaire   +1 more source

GLP-1RA associated with diabetic retinopathy?

Reactions Weekly, 2019
openaire   +1 more source

Exclusion of Older Adults from Obesity Treatment Pivotal Trials of GLP-1RAs and GIP/GLP-1RAs

Journal of General Internal Medicine
Alissa S. Chen, Yixuan Liang, Kasia J. Lipska, Joseph S. Ross, Reshma Ramachandran   +4 more
openaire   +1 more source